Goldman Sachs has initiated coverage of Mineralys Therapeutics (NASDAQ:MLYS) with a buy rating, citing upcoming data for its hypertension drug candidate lorundrostat. The investment bank said it ...

they fared worse on average than in last year’s test. According to a Bank of America report out Thursday, the “worst hit” was Goldman Sachs, with a year-over-year increase of roughly 100 ...

However, the Goldman Sachs example shows us another ... Firms that succeed at corporate innovation are willing to move slowly to test every element of a business model before investing.

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...